Status:
COMPLETED
1% Chloroprocaine(PF) vs. Bupivacaine Spinals
Lead Sponsor:
Montefiore Medical Center
Conditions:
Return of Motor and Sensory Blockade
Anesthesia, Spinal
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The use of 1% Chloroprocaine (PF) spinal anesthesia will reduce the recovery times and discharge time of patients undergoing hemorrhoidectomies as compared to 0.75% bupivacaine spinal. The primary obj...
Detailed Description
The use of 1% Chloroprocaine (PF) spinal anesthesia will reduce the recovery times and discharge time of patients undergoing hemorrhoidectomies as compared to 0.75% bupivacaine spinal. The primary obj...
Eligibility Criteria
Inclusion
- Patient undergoing anorectal procedures
- Age 18 and above
- American Society of Anesthesiologist Physical Status (ASA), I-III
Exclusion
- Patient refusal
- Inability to understand and sign informed consent
- Allergic reaction to bupivacaine or other local anesthetics
- Coagulopathy (INR \>= 1.5)
- Use of anticoagulant drugs (Plavix, Coumadin)
- Thrombocytopenia (Platelets \< 100,000)
- Infection at the site
- Increased intracranial pressure
- Unstable spine, Spine abnormalities
- History of atypical cholinesterase (CP is metabolized by cholinesterase)
- Diagnosis of any disorders (i.e., benign prostatic hyperplasia, cystitis, vulvovaginitis) that would delay voiding
- Anticipated procedure time longer than 60 minutes
Key Trial Info
Start Date :
September 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2023
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT03324984
Start Date
September 11 2019
End Date
February 1 2023
Last Update
February 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montefiore Medical Center
The Bronx, New York, United States, 10467